IP Library Granted Patent US 11,066,646
Granted Patent B2
US 11,066,646 · App. 15/910,625 · Granted Jul 20, 2021

Brown fat cell compositions and methods

Inventors: Francisco Javier Silva (Melville, NY); Mark Weinreb (Melville, NY); Amit N. Patel (Salt Lake City, UT); David A. Bull (Salt Lake City, UT)
Assignee: BIORESTORATIVE THERAPIES, INC.
C12N5/0667A61K35/35C12N5/0653G01N33/502G01N33/5044A61K35/28C12N2500/84C12N2500/98C12N2501/01C12N2501/02C12N2501/33C12N2501/385C12N2501/39C12N2501/395C12N2506/1384Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,066,646
App. No.
15/910,625
Granted
Jul 20, 2021
Kind
B2
Abstract

Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment, the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.

Claims (21)

1. A method of generating a population of human brown fat adipocytes, the method comprising:

removing a human stem cell from human brown adipose tissue;

differentiating the human stem cell into a population of human brown fat adipocytes in a culture medium under a selective pressure of 0 to 5% oxygen, wherein the culture medium does not comprise a xenogenic animal product and comprises fibronectin type III domain-containing protein 5 (FNDC), insulin, dexamethasone, isobutylmethylxanthine, indomethacin, triiodothyronine (T3), rosiglitazone, and 0.5% to 20% human platelet lysate.

2. The method of claim 1 , further comprising: providing the population of human brown fat adipocytes for implantation into a subject.

3. The method of claim 1 , wherein the selective pressure is 1 to 5% oxygen.

4. The method of claim 2 , wherein the population of human brown fat adipocytes is allogeneic.

5. The method of claim 2 , wherein the population of human brown fat adipocytes is autogeneic.

6. The method of claim 1 , wherein the culture medium comprises 10-20% human platelet lysate.

7. The method of claim 4 , further comprising:

implanting the allogeneic population of human brown fat adipocytes into a subject to be treated.

8. The method of claim 7 , wherein the allogenic population of human brown fat adipocytes comprises 10 5 -10 10 .

9. The method of claim 5 , further comprising:

implanting the autogeneic population of human brown fat adipocytes into a subject to be treated.

10. The method of claim 9 , wherein the autogeneic population of human brown fat adipocytes comprises 10 5 -10 10 cells.

11. The method of claim 1 , further comprising:

isolating exosomes from the culture medium of the population of human brown fat adipocytes.

12. A method of generating a population of human brown fat adipocytes, the method comprising:

differentiating a human stem cell into a population of human brown fat adipocytes in a first culture medium under a selective pressure of 0 to about 5% oxygen, wherein the first culture medium does not comprise a xenogenic animal product and consists of: insulin, dexamethasone, isobutylmethylxanthine, indomethacin, triiodothyronine (T3), rosiglitazone, and 0.5 to 20% human platelet lysate;

removing the first culture medium;

further differentiating the human stem cell into the population of human brown fat adipocytes in a second culture medium under a selective pressure of 0 to about 5% oxygen wherein the second culture medium does not comprise a xenogenic animal product and consists of: insulin, dexamethasone, isobutylmethylxanthine, indomethacin, triiodothyronine (T3), rosiglitazone, fibronectin type III domain-containing protein 5 (FNDC5), and 0.5 to 20% human platelet lysate

wherein the human stem cell is removed from human brown adipose tissue.

Assignments (6)
SECURITY INTEREST Recorded Feb 25, 2020
From: BIORESTORATIVE THERAPIES, INC.
To: DESMARAIS, JOHN M.
Reel/Frame 051914/0050 →
SECURITY INTEREST Recorded Dec 20, 2019
From: BIORESTORATIVE THERAPIES, INC.
To: TUXIS TRUST; DESMARAIS, JOHN M.
Reel/Frame 051347/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: WEINREB, MARK; SILVA, FRANCISCO JAVIER
To: BIORESTORATIVE THERAPIES, INC.
Reel/Frame 048370/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: PATEL, AMIT N.; BULL, DAVID A.
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 048370/0548 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: PATEL, AMIT N.
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 048370/0895 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: UNIVERSITY OF UTAH RESEARCH FOUNDATION
To: BIORESTORATIVE THERAPIES, INC.
Reel/Frame 048370/0917 →
Continuity (6)
Continuation 13932468 · Jul 1, 2013
Continuation 13536564 · Jun 28, 2012
Provisional Application 61502508 · Jun 29, 2011
Provisional Application 61632122 · Jan 18, 2012
Provisional Application 61632516 · Jan 25, 2012
Related Publication 20190040361A1 · Feb 7, 2019